Biotech Values

[biotech jim]

ALDR and its anti-CGRP mAb for migraine is the real deal. These CGRP/CGRP receptor mAbs and the receptor blocking small molecules should be great from the perspective of both clinicians and migraineurs. By the way, this past spring I finally read Oliver Sacks book Migraine (somewhat outdated now but still a good clinical read) but it does not speak much to new treatments nor to recent brain imaging data. Migraine research remains a hot and exciting area of clinical investigation.

I personally would not invest in ALDR at this time, due to its high current valuation of ~$2B., the intense competition in this area, and the potential pushback at price for the mAbs for this devastating disorder. The time to have bought ALDR was a year ago or so, just after having gone public.

Oliver Sacks quote from 1984:

"If migraine patients have a common and legitimate second complaint besides their migraines, it is that they have not been listened to by physicians. Looked at, investigated, drugged, charged, but not listened to."